Delivery Order SPE2DR25D3014-SPE2DR26FP1RW
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,013.75 to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (30 single-use vials) on January 8, 2026, with an ultimate completion date of January 9, 2026. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. AmerisourceBergen Drug Corp operates as...
- The Defense Logistics Agency awarded a delivery order valued at $1,923.36 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60 units) on January 16, 2026, with an ultimate completion date of January 20, 2026. This is a firm fixed-price, non-set-aside contract with performance taking place in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc., which holds a significant indefinite delivery contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,082.10 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60 count) on January 22, 2026, with an ultimate completion date of January 23, 2026. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office, with performance to be fulfilled from the company's Conshohocken, Pennsylvania location. The award falls under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,541.08 for Restasis 0.05% Eye Emulsion (30-count units) on May 6, 2025, with an ultimate completion date of May 7, 2025. This firm fixed-price delivery order represents a non-competitive procurement under a larger indefinite delivery contract vehicle. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $6,297.40 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (60-unit package). This non-set-aside, competitively awarded contract features firm fixed pricing and is scheduled for completion by July 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Restasis 0.05% Eye Emulsion in 30-count units. The contract was competitively awarded on January 23, 2026, with a ceiling value of $23,706.33 and a firm fixed-price structure. The order is scheduled for ultimate completion by January 26, 2026, with performance to take place at AmerisourceBergen's Conshohocken facility....
- The Defense Logistics Agency awarded a $4,560.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 23, 2026, for the supply of Restasis 0.05% eye emulsion (30 count). The order, with an ultimate completion date of January 26, 2026, is a non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. This pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a $10,783.83 firm fixed-price delivery order for Restasis 0.05% Eye Emulsion (60 units), with an ultimate completion date of December 5, 2025. This is a competitively awarded, non-set-aside contract with performance taking place at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $4,871.29 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30 single-dose units) on December 17, 2025, with an ultimate completion date of December 18, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $1,340.35 to AmerisourceBergen Drug Corp for supply of Restasis 0.05% Eye Emulsion (60 count) on January 15, 2026, with a completion date of January 16, 2026. This firm fixed-price delivery order was competitively awarded without set-aside designation and is being performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical...
- SPE2DR25D3014Indefinite Delivery Contract
- SPE2DR25D3014-SPE2DR26FP1RWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,340.01 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60 units) on January 23, 2026, with an ultimate completion date of January 26, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The contractor's place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is executed under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031, which serves as the primary vehicle for supplying comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen is a major pharmaceutical distributor and critical federal vendor specializing in brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through competitively awarded contracts. This delivery order for Restasis, an ophthalmic treatment, represents a routine medical procurement supporting the broader pharmaceutical supply requirements of military treatment facilities and federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 1/22/26 |